“`html
Positive
- Over 94% of patients reported movement improvement with AUSTEDO XR
- High patient satisfaction rates exceeding 89%
- 96% of patients expressed interest in continuing treatment
- More than 77% reported improved social comfort and emotional well-being
- Strong ease of use with over 96% reporting medication was easy to take
Insights
Teva’s AUSTEDO XR shows strong patient satisfaction and symptom
improvement in real-world survey, strengthening its position in the TD treatment market.
Teva’s announcement of real-world patient survey data for AUSTEDO XR
(deutetrabenazine) extended-release tablets provides compelling evidence of the
medication’s effectiveness in treating tardive dyskinesia (TD). The survey of 209 patients
revealed remarkably high satisfaction rates, with over 94% reporting movement
improvement and over 89% expressing overall satisfaction with the treatment.
What’s particularly noteworthy is that these positive results were consistent across both
patient groups studied – those with prior valbenazine use (PVU) and those with no prior
treatment (de novo). The fact that 96% of patients expressed interest in continuing
treatment suggests strong patient retention potential, a crucial factor for sustained market
performance.
Beyond the physical symptom improvements, the data demonstrates AUSTEDO XR’s impact on
quality of life metrics, with over 77% of patients reporting increased comfort in social
settings and improved emotional well-being. This holistic benefit profile strengthens the
medication’s value proposition in a competitive market.
The high ease-of-use rating (over 96%) and patient appreciation for dose adjustment
flexibility (over 82%) highlight the practical advantages of AUSTEDO XR’s formulation.
These factors can drive patient preference and adherence, potentially differentiating
AUSTEDO XR from competitors in the TD treatment landscape.
This real-world evidence complements clinical trial data and provides healthcare providers
with valuable insights into patient experiences, potentially supporting broader adoption of
AUSTEDO XR in clinical practice. The data presentation at the Psych Congress Annual Meeting
ensures visibility among key prescribers, which could translate to prescription growth for
this important product in Teva’s neurology portfolio.
09/20/2025 – 10:16 PM
Key findings from the survey included a significant improvement in social comfort and emotional well-being, with 77% of
patients reporting positive changes in these areas. Furthermore, 96% of patients found the medication easy to
administer, highlighting the user-friendly nature of AUSTEDO XR. Notably, the study encompassed both patients with
prior valbenazine (another TD treatment) usage and those who were treatment-naive. A striking 96% of participants
expressed a desire to continue treatment with AUSTEDO XR, underscoring patient satisfaction and perceived benefit.
Dr. Eric Hughes, Executive Vice President, Global R&D and Chief Medical Officer at Teva, emphasized the company’s
commitment to understanding the lived experiences of individuals with TD. “At Teva, we feel a profound responsibility to
ensure we’re not just treating TD, but truly understanding the lived experiences of this community,” he stated.
These findings suggest that AUSTEDO XR offers a valuable option for managing TD symptoms, improving both motor control and
quality of life for patients. With a substantial portion of patients eager to continue treatment, AUSTEDO XR is
demonstrating promising clinical utility.
The market for TD treatments is expected to grow in the coming years, driven by increasing awareness of the condition and
advances in therapeutic options. AUSTEDO XR’s positive real-world data, coupled with its convenient once-daily
formulation, positions Teva to capture a significant share of this expanding market. The extended-release formula offers
potentially improved adherence compared to more frequent dosing regimens. Furthermore, the revealed improvements in
emotional wellbeing open a new avenue for treatment for TD, going beyond just motor skills.
These survey results underscore the comprehensive benefits of AUSTEDO XR, affirming its role as a compelling treatment option
for tardive dyskinesia. With its focus on patient-centric outcomes, Teva is poised to make a substantial impact on the
lives of those affected by this challenging condition. Industry analysts are carefully watching AUSTEDO XR’s performance,
as its growth could significantly contribute to Teva’s overall revenue in the neuroscience sector.
Teva is dedicated to addressing patients needs now and in the future. To learn more visit www.tevapharm.com.
FAQ
What were the key findings of the AUSTEDO XR patient survey by Teva (NYSE: TEVA)?
The survey showed that over 94% of patients reported movement improvement, more than 89% expressed high
satisfaction, and 96% found the medication easy to take.
How many patients participated in the AUSTEDO XR tardive dyskinesia study?
The study included 209 participants with tardive dyskinesia, including 54 with prior valbenazine use and 100
with no prior treatment.
What percentage of AUSTEDO XR patients reported improved social and emotional well-being?
More than 77% of patients reported that their reduction in movements led to more comfort in social settings and
improved emotional well-being.
What was the patient satisfaction rate with AUSTEDO XR for tardive dyskinesia?
Patient satisfaction rates were 91% for those with prior valbenazine use and 89% for new patients, with 96%
expressing interest in continuing treatment.
When were these AUSTEDO XR results presented?
The results were presented at the 2025 Psych Congress Annual Meeting on September 20, 2025 in San Diego,
California.
“`
Original article, Author: Jam. If you wish to reprint this article, please indicate the source:https://aicnbc.com/9698.html
